Bora Pharmaceuticals Co., Ltd./ADR
No enriched coverage for $BORAY in the last 7 days.
No SEC Form 4 filings for $BORAY in the last 30 days.
See all $BORAY insider activity →Bora Pharmaceuticals (TWSE:6472, OTCQX:BORAY) reported 2Q26 record revenue of NT$5,889m, up 47.2% QoQ, with basic EPS of NT$4.36. Gross margin rose to 41.3% and operating margin to 16.8% (about 18% excluding one-time Weider costs). CDMO backlog was US$317m. The company updated 2026 outlook and added a Consumer Healthcare segment.
Strong sequential margin expansion and record backlog support a bullish near-term risk/reward, but FDA audit timing could shift 3Q revenue recognition.
alphai scores every news story that mentions BORAY with an AI model for sentiment and relevance, and aggregates insider trades from Bora Pharmaceuticals Co., Ltd./ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bora Pharmaceuticals (TWSE:6472, OTCQX:BORAY) reported 2Q26 record revenue of NT$5,889m, up 47.2% QoQ, with basic EPS of NT$4.36. Gross margin rose to 41.3% and operating margin to 16.8% (about 18% excluding one-time Weider costs). CDMO backlog was US$317m. The company updated 2026 outlook and added a Consumer Healthcare segment.
6 min read
